| |
Original Artikel |
Datum |
Titel |
Autoren Max. 6 Autoren |
| 1 |
[GO] |
2026―Jan―08 |
Erratum: Support Vector Machine Identification of Small Molecule Binders to an Understudied Allosteric Site of SARS-CoV-2 Mpro for Next-Generation PROTAC-Based Therapeutics |
|
| 2 |
[GO] |
2025―Dez―23 |
Sequential Optimization Approach Toward an Azapeptide-Based SARS-CoV-2 Main Protease Inhibitor |
Rabea Voget, Victoria Steiger, Julian Breidenbach, Katharina Sylvester, Christin Müller-Ruttloff, Chun-Chiao Yang, John Ziebuhr, Norbert Sträter, Christa E. Müller, Michael Gütschow |
| 3 |
[GO] |
2025―Dez―13 |
Support Vector Machine Identification of Small Molecule Binders to an Understudied Allosteric Site of SARS-CoV-2 Mpro for Next-Generation PROTAC-Based Therapeutics |
Enrico Mario Alessandro Fassi, Nedra Mekni, Marco Albani, Sabine Maehrlein, Annabelle Carolin Weldert, Tanja Schirmeister, Thierry Langer, Giovannf razioso |
| 4 |
[GO] |
2025―Nov―29 |
Exploring Nirmatrelvir Derivatives Through P2 Substituent Modifications and Warhead Innovations Targeting the Main Protease of SARS-CoV-2 |
Felipe Cardoso Prado Martins, Johannes Lang, Fernanda dos Reis Rocho, Xianxian Wang, Vinícius Bonatto, Jerônimo Lameira, Christian Klein, Carlos Alberto Montanari |
| 5 |
[GO] |
2025―Sep―09 |
Synthesis and Evaluation of Thiosemicarbazone Inhibitors for SARS-CoV-2 Mpro by Spectroscopy and Microscale Thermophoresis |
Leyao Chen, Xinluan Lv, Xiaoyu Chang, Ruiyong Wang |
| 6 |
[GO] |
2025―Jan―28 |
Synthesis and biological investigation of peptidomimetic SARS-CoV-2 main protease inhibitors bearing quinoline-based heterocycles at P3 |
Sara Rossi, Graziano Deidda, Lia Fiaschi, Roberta Ibba, Mariachiara Pieroni, Maria Dichiara, Gabriele Carullo, Stefania Butini, Anna Ramunno, Simone Brogi, Marco Lolicato, Cristina Arrigoni, Noemi Cabella, Laura Bavagnoli, Giovanni Maga, Ilenia Varasi, Camilla Biba, Ilaria Vicenti, Sandra Gemma, Emmanuele Crespan, Maurizio Zazzi, Giuseppe Campiani |
| 7 |
[GO] |
2024―Dez―09 |
Phthalimide derivatives as a new class of papain-like protease inhibitors in SARS-CoV-2 |
Thomas Fischer, David Frasson, Martin Sievers, Rainer Riedl |
| 8 |
[GO] |
2024―Nov―09 |
Antiviral efficacy of heparan sulfate and enoxaparin sodium against SARS-CoV-2 |
Virginia Fuochi, Salvatore Furnari, Giuseppe Floresta, Vincenzo Patamia, Chiara Zagni, Filippo Drago, Antonio Rescifina, Pio Maria Furneri |
| 9 |
[GO] |
2024―Aug―16 |
Synthesis, in vitro and in silico evaluation of gallamide and selenogallamide derivatives as inhibitors of the SARS-CoV-2 main protease |
Maryelle A. G. de Carvalho, Gabriella B. Souza, Tiago Tizziani, Carime L. M. Pontes, Bibiana P. Dambrós, Natália F. de Sousa, Marcus T. Scotti, Mario Steindel, Antonio L. Braga, Louis P. Sandjo, Francisco F. de Assis |
| 10 |
[GO] |
2024―Aug―06 |
An in-depth analysis of COVID-19 treatment: Present situation and prospects |
Md Ariful Islam, Kalyani Pathak, Riya Saikia, Pallab Pramanik, Aparoop Das, Prasenjit Talukdar, Anshul Shakya, Surajit Kumar Ghosh, Udaya Pratap Singh, Hans Raj Bhat |
| 11 |
[GO] |
2024―Apr―22 |
Spectroscopic investigation and structural simulation in human serum albumin with hydroxychloroquine/Silybum marianum and a possible potential COVID-19 drug candidate |
Maryam S. H. Tekyeh, Seyed M. M. Shushtarian, Alireza I. Bakhsh, Saeed H. Tackallou, Hossein Lanjanian |
| 12 |
[GO] |
2023―Dez―13 |
Combating DC-SIGN-mediated SARS-CoV-2 dissemination by glycan-mimicking polymers |
Jonathan Cramer, Xiaohua Jiang, Butrint Aliu, Beat Ernst |
| 13 |
[GO] |
2023―Okt―19 |
In vitro antiviral activity of favipiravir and its 6- and 3-O-substituted derivatives against coronavirus: Acetylation leads to improvement of antiviral activity |
Valeria Elizalde, Santiago Mirazo, Angel H. Romero, Guzman Alvarez |
| 14 |
[GO] |
2023―Okt―16 |
Exploration of 1,2,3-triazolo fused triterpenoids as inhibitors of human coronavirus 229E targeting the viral nsp15 protein |
Rui Wang, Annelies Stevaert, Tien Nguyen Truong, Qifei Li, Besir Krasniqi, Benjamin Van Loy, Arnout Voet, Lieve Naesens, Wim Dehaen |
| 15 |
[GO] |
2023―Okt―13 |
Evaluation of in vitro SARS-CoV-2 inactivation by a new quaternary ammonium compound: Bromiphen bromide |
Sergio Strizzi, G. Cappelletti, M. Biasin, Angelica Artasensi, Laura Fumagalli, Antonella Casiraghi |
| 16 |
[GO] |
2023―Mai―31 |
Inhibitory effects of 190 compounds against SARS-CoV-2 Mpro protein: Molecular docking interactions |
Gabriella B. Souza, Larissa Sens, Stefan J. Hammerschmidt, Natália F. de Sousa, Maryelle A. G. de Carvalho, Carlos V. D. Dos Santos, Tiago Tizziani, Monalisa A. Moreira, Luiz A. E. Pollo, Erlon F. Martin, José S. S. Neto, Maique W. Biavatti, Francisco F. de Assis, Bonaventure T. Ngadjui, Ingrid K. Simo, Pantaléon Ambassa, Marcus T. Scotti, Luciana Scotti, Antonio L. Braga, Tanja Schirmeister, Louis P. Sandjo |
| 17 |
[GO] |
2023―Jan―24 |
Blood pH and COVID-19 |
Mahmoud Fahmi Elsebai, EL-Sayed E. Habib |
| 18 |
[GO] |
2022―Nov―01 |
BC-11 is a covalent TMPRSS2 fragment inhibitor that impedes SARS-CoV-2 host cell entry |
Aurélien F. A. Moumbock, Hoai T. T. Tran, Evelyn Lamy, Stefan Günther |
| 19 |
[GO] |
2022―Jun―08 |
Ginkgo biloba
in the management of the COVID-19 severity |
Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Ajeet Kaushik, Małgorzata Kujawska, Gaber El-Saber Batiha |
| 20 |
[GO] |
2022―Mai―24 |
Thiazole-based SARS-CoV-2 protease (COV M
pro
) inhibitors: Design, synthesis, enzyme inhibition, and molecular modeling simulations |
Reham W. Elsayed, Mohamed A. Sabry, Hussein I. El-Subbagh, Said M. Bayoumi, Selwan M. El-Sayed |
| 21 |
[GO] |
2022―Mrz―04 |
Implication of in silico studies in the search for novel inhibitors against SARS-CoV-2 |
Farak Ali, Shahnaz Alom, Anshul Shakya, Surajit K. Ghosh, Udaya P. Singh, Hans R. Bhat |
| 22 |
[GO] |
2022―Jan―18 |
A comprehensive update on the structure and synthesis of potential drug targets for combating the coronavirus pandemic caused by SARS-CoV-2 |
Prerna Malik, Sonika Jain, Pankaj Jain, Jyoti Kumawat, Jaya Dwivedi, Dharma Kishore |
| 23 |
[GO] |
2021―Nov―21 |
Activating endogenous resolution pathways by soluble epoxide hydrolase inhibitors for the management of COVID-19 |
Manoj Manickam, Sangeetha Meenakshisundaram, Thanigaimalai Pillaiyar |
| 24 |
[GO] |
2021―Aug―24 |
Binding of boswellic acids to functional proteins of the SARS-CoV-2 virus: Bioinformatic studies |
Reinhard H. Caliebe, Thomas Scior, Hermann P. T. Ammon |
|
